register

Digital & Innovation

World first for AI in drug discovery

Health Industry Hub | February 3, 2020 |

A drug molecule developed by artificial intelligence (AI) will be used in human trials in a world first for machine learning in medicine.

DSP-1181 was created through the joint research by Japanese pharmaceuticals company Sumitomo Dainippon Pharma and UK start-up Exscientia, with Sumitomo Dainippon Pharma providing its experience and knowledge in monoamine GPCR drug discovery and Exscientia applying its Centaur Chemist Artificial Intelligence (AI) platform for drug discovery.

This project was delivered by the strong synergy of the joint research, requiring less than 12 months to complete the exploratory research phase, just a fraction of the typical average of 4.5 years using conventional research techniques.

DSP-1181 is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist, and its phase I clinical study to treat obsessive-compulsive disorder as an indication candidate.

Andrew Hopkins, CEO of Exscientia, said: “We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery.”

“We have seen AI for diagnosing patients and for analysing patient data and scans, but this is a direct use of AI in the creation of a new medicine. The molecule – known as DSP-1181 – was created by using algorithms that sifted through potential compounds, checking them against a huge database of parameters. There are billions of decisions needed to find the right molecules and it is a huge decision to precisely engineer a drug,” said Prof Hopkins.

“But the beauty of the algorithm is that they are agnostic, so can be applied to any disease,” he added.

AI displays a significant potential to enhance and accelerate drug discovery considering the substantial cost of research and development and the need for innovative medicines to enhance patient outcomes.


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.